A phase 2 study of intravenous pembrolizumab and intratumorally injected autologous dendritic cells (DCs) in refractory colorectal cancer (CRC). This is an ASCO Meeting Abstract from the 2025 ASCO ...
Combination of hSTC810 and capecitabine therapy in metastatic colorectal cancer with resistance or intolerance to oxaliplatin and irinotecan-based chemotherapy: A single arm, phase 1b/2, multicenter ...
CINCINNATI (WKRC) - A drug to fight cancer made right in the Tri-State is now in trials all across the country. It's called BXQ-350 and its now in clinical trials to potentially have a dual purpose - ...
Bexion's lead drug candidate is BXQ-350, a first-in-class biologic containing the multifunctional sphingolipid activator protein, Saposin C, and a phospholipid. Multiple Phase 1 clinical trials in ...
"These data provide a large body of work on the use of BXQ-350 in patients," said Robert Wesolowski, MD, Clinical Professor of Internal Medicine at the James Cancer hospital and the Ohio State ...
The first clinical trials of a new drug that targets solid cancer tumors has now been tested. The Phase 1A clinical trials mark the first time ever the drug, called BXQ-350, was used in people.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results